ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0163

Plasma Exchange to Treat Patients with Severe COVID-19

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Nusshag, Christian, Heidelberg University Hospital Departement of Nephrology, Heidelberg, Germany
  • Morath, Christian, Heidelberg University Hospital Departement of Nephrology, Heidelberg, Germany
  • Speer, Claudius, Heidelberg University Hospital Departement of Nephrology, Heidelberg, Germany
  • Kälble, Florian, Heidelberg University Hospital Departement of Nephrology, Heidelberg, Germany
  • Zeier, Martin G., Heidelberg University Hospital Departement of Nephrology, Heidelberg, Germany
  • Boxberger, Monica, Heidelberg University Hospital Deparement of Gastroenterology, Heidelberg, Germany
  • Schulze Schleithoff, Anna Elisa, Heidelberg University Hospital Deparement of Gastroenterology, Heidelberg, Germany
  • Weigand, Markus A., Heidelberg University Hospital Departement of Anesthesiology, Heidelberg, Germany
  • Merle, Uta, Heidelberg University Hospital Deparement of Gastroenterology, Heidelberg, Germany
Background

The clinical spectrum of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to critical illness and death in up to 89% of mechanically ventilated patients. Therefore, new therapeutic strategies are needed. Recent evidence suggests a multi-level inflammatory syndrome in some of the most critically ill patients with overlapping features of other hyperinflammatory or autoimmune diseases. Thus, plasma exchange (PE) has become a subject of controversy as potential therapy in these patients. Here, we report the results of the so far largest cohort of critically ill COVID-19 patients treated with PE.

Methods

All critically ill COVID-19 patients treated with PE at Heidelberg University Hospital were analyzed between April and December 2020. Disease course and outcomes were compared with a standard care control group matched for age, sex, and disease severity. Changes in laboratory and clinical parameters were studied longitudinally. Kaplan-Meier and Cox regression analyses were performed.

Results

In total, 28 critically ill COVID-19 patients were treated with an average of 3 PE procedures per patient. No relevant complications occurred during PE therapy. Inflammatory markers and biochemical indicators of end-organ damage and endothelial activation were significantly reduced during PE. These laboratory changes were accompanied by normalization of body temperature, improved pulmonary function, and reduced vasopressor demand. Most importantly, the laboratory and clinical improvements were maintained after the last PE. In contrast, most parameters in the control group did not improve significantly over seven days, although baseline clinical and laboratory parameters were comparable in both groups. Kaplan-Meier analysis showed improved 30-day survival in the PE group compared to the control group (67.9% vs. 42.9%, p=0.044). In a multivariable analysis, the hazard ratio for death was 0.27 (95% CI 0.11-0.68, p=0.005) with PE versus standard care.

Conclusion

Our data further suggest that PE represents a potential therapeutic strategy for a subset of severe COVID-19 cases. The observed PE-related effects appear to go beyond a purely artificial improvement in blood parameters and may indicate a reversal of the complex COVID-19 immunopathology. Randomized controlled trials are urgently needed.